Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R ...

Low and high high-density lipoprotein (HDL) are associated with an increased risk for age-related macular degeneration (AMD), ...

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding ...

Although cures for age-related macular degeneration are elusive, the case for prevention through nutrition looks strong and ...

A new study from the National Eye Institute has found that eating foods high in dietary nitrates—mainly from vegetables—may ...

Galimedix Therapeutics completed the single ascending dose part of a phase 1 study of GAL-101, a potential oral therapy under ...

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in ...